APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ondansetron

Ondansetron is a synthetic, small-molecule 5-HT3 receptor antagonist used as an antiemetic for prevention and treatment of nausea and vomiting driven by serotonin release, most prominently chemotherapy-induced and postoperative settings.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Ondansetron is a synthetic, small-molecule 5-HT3 receptor antagonist used as an antiemetic for prevention and treatment of nausea and vomiting driven by serotonin release, most prominently chemotherapy-induced and postoperative settings. It is marketed predominantly as the racemate. The free-base molecular formula is C18H19N3O (molecular weight 293.36 g/mol). A commonly used systematic chemical name is (RS)-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one; commercial products are frequently supplied as ondansetron hydrochloride (often with defined hydration state) to improve handling and aqueous solubility in finished dosage forms.

From a physicochemical standpoint, ondansetron is a weakly basic heteroaromatic ketone (imidazole nitrogen as the principal basic site), typically encountered as an off-white crystalline solid. The free base is sparingly soluble in water with moderate lipophilicity (logP in the low-to-mid single digits), while the hydrochloride salt is substantially more water-soluble and therefore preferred for oral solutions and injectables. Industrial synthesis is generally executed by constructing the carbazol-4-one core (via stepwise ring-forming cyclization on a suitably substituted bicyclic precursor), introducing a 3-(halomethyl) or equivalent electrophilic handle, then performing N-alkylation of 2-methylimidazole to install the imidazolylmethyl side chain; the active base is finally converted to the hydrochloride (and, where applicable, crystallized to a controlled hydrate) under tightly controlled crystallization and polymorph control conditions.

Pharmacologically, ondansetron is a potent and selective antagonist of the 5-HT3 ligand-gated ion channel, blocking serotonin-mediated signaling on peripheral vagal afferents in the gastrointestinal tract and centrally within the chemoreceptor trigger zone and vomiting center, thereby suppressing the emetogenic reflex without relying on dopamine D2 receptor blockade. After oral administration, systemic exposure is limited by first-pass metabolism and shows moderate bioavailability; peak concentrations typically occur within a few hours. Distribution is extensive with moderate plasma protein binding. Clearance is predominantly hepatic oxidative metabolism (CYP3A4 as a major contributor, with CYP2D6 and CYP1A2 also participating), with metabolites eliminated in urine and feces and only a minor fraction recovered unchanged; the terminal half-life in healthy adults is on the order of several hours and is meaningfully prolonged in hepatic impairment, which is the clinically relevant driver for dose limitation in that population.

The research object may be an ingredient, device, preparation or care service. These supply stages have different specifications and measurement units; an ingredient identity or device name does not establish a clinical outcome.

What turns activity into demand

Qualified use at the specified treatment or instrument boundary creates purchases through protocol, utilisation and replacement. A product, clinical service and complete care episode measure different supplied objects.

The commercial boundary

For Ondansetron, distinguish the supplied product from its inputs and the complete application. Report types and applications may overlap; retain the selected edition's product definition, geography, period, unit and transaction basis when comparing estimates.

Which conditions determine usable ondansetron performance?

Ondansetron is a synthetic, small-molecule 5-HT3 receptor antagonist used as an antiemetic for prevention and treatment of nausea and vomiting driven by serotonin release, most prominently chemotherapy-induced and postoperative settings. Confirm the specified composition or device function, intended use and supplied unit. Separate ingredients, finished preparations, equipment and treatment activity before comparing quantities or revenue; use the report scope rather than inferring efficacy from an illustration.

Selected research

Market Outlook & Growth Opportunities

Global Ondansetron Market Outlook and Growth Opportunities 2026

15 January 2026213 pages

Choose your research edition.

Industry ResearchOndansetron Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Ondansetron Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Ondansetron Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ondansetron Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Ondansetron Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

Ondansetron is a synthetic, small-molecule 5-HT3 receptor antagonist used as an antiemetic for prevention and treatment of nausea and vomiting driven by serotonin release, most prominently chemotherapy-induced and postoperative settings. It is marketed predominantly as the racemate. The free-base molecular formula is C18H19N3O (molecular weight 293.36 g/mol). A commonly used systematic chemical name is (RS)-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one; commercial products are frequently supplied as ondansetron hydrochloride (often with defined hydration state) to improve handling and aqueous solubility in finished dosage forms.

From a physicochemical standpoint, ondansetron is a weakly basic heteroaromatic ketone (imidazole nitrogen as the principal basic site), typically encountered as an off-white crystalline solid. The free base is sparingly soluble in water with moderate lipophilicity (logP in the low-to-mid single digits), while the hydrochloride salt is substantially more water-soluble and therefore preferred for oral solutions and injectables. Industrial synthesis is generally executed by constructing the carbazol-4-one core (via stepwise ring-forming cyclization on a suitably substituted bicyclic precursor), introducing a 3-(halomethyl) or equivalent electrophilic handle, then performing N-alkylation of 2-methylimidazole to install the imidazolylmethyl side chain; the active base is finally converted to the hydrochloride (and, where applicable, crystallized to a controlled hydrate) under tightly controlled crystallization and polymorph control conditions.

Pharmacologically, ondansetron is a potent and selective antagonist of the 5-HT3 ligand-gated ion channel, blocking serotonin-mediated signaling on peripheral vagal afferents in the gastrointestinal tract and centrally within the chemoreceptor trigger zone and vomiting center, thereby suppressing the emetogenic reflex without relying on dopamine D2 receptor blockade. After oral administration, systemic exposure is limited by first-pass metabolism and shows moderate bioavailability; peak concentrations typically occur within a few hours. Distribution is extensive with moderate plasma protein binding. Clearance is predominantly hepatic oxidative metabolism (CYP3A4 as a major contributor, with CYP2D6 and CYP1A2 also participating), with metabolites eliminated in urine and feces and only a minor fraction recovered unchanged; the terminal half-life in healthy adults is on the order of several hours and is meaningfully prolonged in hepatic impairment, which is the clinically relevant driver for dose limitation in that population.

Read the full market overview

The global Ondansetron market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Ondansetron is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Ondansetron is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Asia Pacific market for Ondansetron is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Ondansetron market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Ondansetron market include Sun Pharmaceuticals, Sandoz, Qilu Pharmaceutical, Fuan Pharmaceutical, PKU HealthCare, Wockhardt, Aelida Healthcare, Beijing Sciecure Pharmaceutical and Jiangsu Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Ondansetron market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Ondansetron and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Ondansetron sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Ondansetron market size, projected growth trends, production technologies, key applications, and end-use industries.

Ondansetron Segment by Company

Sun Pharmaceuticals

Sandoz

Qilu Pharmaceutical

Fuan Pharmaceutical

PKU HealthCare

Wockhardt

Aelida Healthcare

Beijing Sciecure Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Fosun Pharma

Harbin Medisan

CTX Lifesciences

Pfizer

Viatris

Dr. Reddy's Laboratories

Aurobindo Pharma

Zydus Lifesciences

Lupin

Hikma Pharmaceuticals

Fresenius Kabi

Baxter Pharmaceuticals

Ondansetron Segment by Type

Tablets (including ODT)

Injection

ODF/OSF

Other

Ondansetron Segment by Application

Hospital pharmacies

Retail pharmacies

Online pharmacies

Ondansetron Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Ondansetron status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Ondansetron market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Ondansetron significant trends, drivers, influence factors in global and regions.

6. To analyze Ondansetron competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ondansetron market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ondansetron and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ondansetron.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Ondansetron market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ondansetron industry.

Chapter 3: Detailed analysis of Ondansetron manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Ondansetron in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Ondansetron in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Ondansetron Industry Trends Table 2. Ondansetron Industry Drivers Table 3. Ondansetron Industry Opportunities and Challenges Table 4. Ondansetron Industry Restraints Table 5. Global Ondansetron Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Ondansetron Revenue Share by Company (2021-2026) Table 7. Global Ondansetron Sales Volume by Company (kg) & (2021-2026) Table 8. Global Ondansetron Sales Volume Share by Company (2021-2026) Table 9. Global Ondansetron Average Price (USD/g) of Company (2021-2026) Table 10. Global Ondansetron Company Ranking, (2024-2026) & (USD Million) Table 11. Global Ondansetron Key Company Manufacturing Base & Headquarters Table 12. Global Ondansetron Company, Product Type & Application Table 13. Global Ondansetron Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Ondansetron by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Tablets (including ODT) Table 18. Significant Companies of Injection Table 19. Significant Companies of ODF/OSF Table 20. Significant Companies of Other Table 21. Global Ondansetron Sales Volume by Type 2021 VS 2025 VS 2032 (kg) Table 22. Global Ondansetron Sales Volume by Type (2021-2026) & (kg) Table 23. Global Ondansetron Sales Volume by Type (2027-2032) & (kg) Table 24. Global Ondansetron Sales Volume Share by Type (2021-2026) Table 25. Global Ondansetron Sales Volume Share by Type (2027-2032) Table 26. Global Ondansetron Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Ondansetron Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Ondansetron Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Ondansetron Sales Value Share by Type (2021-2026) Table 30. Global Ondansetron Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital pharmacies Table 32. Significant Companies of Retail pharmacies Table 33. Significant Companies of Online pharmacies Table 34. Global Ondansetron Sales Volume by Application 2021 VS 2025 VS 2032 (kg) Table 35. Global Ondansetron Sales Volume by Application (2021-2026) & (kg) Table 36. Global Ondansetron Sales Volume by Application (2027-2032) & (kg) Table 37. Global Ondansetron Sales Volume Share by Application (2021-2026) Table 38. Global Ondansetron Sales Volume Share by Application (2027-2032) Table 39. Global Ondansetron Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Ondansetron Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Ondansetron Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Ondansetron Sales Value Share by Application (2021-2026) Table 43. Global Ondansetron Sales Value Share by Application (2027-2032) Table 44. Global Ondansetron Sales by Region: 2021 VS 2025 VS 2032 (kg) Table 45. Global Ondansetron Sales by Region (2021-2026) & (kg) Table 46. Global Ondansetron Sales Market Share by Region (2021-2026) Table 47. Global Ondansetron Sales by Region (2027-2032) & (kg) Table 48. Global Ondansetron Sales Market Share by Region (2027-2032) Table 49. Global Ondansetron Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Ondansetron Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Ondansetron Sales Value Share by Region (2021-2026) Table 52. Global Ondansetron Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Ondansetron Sales Value Share by Region (2027-2032) Table 54. Global Ondansetron Market Average Price (USD/g) by Region (2021-2026) Table 55. Global Ondansetron Market Average Price (USD/g) by Region (2027-2032) Table 56. Global Ondansetron Sales by Country: 2021 VS 2025 VS 2032 (kg) Table 57. Global Ondansetron Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Ondansetron Sales by Country (2021-2026) & (kg) Table 59. Global Ondansetron Sales Market Share by Country (2021-2026) Table 60. Global Ondansetron Sales by Country (2027-2032) & (kg) Table 61. Global Ondansetron Sales Market Share by Country (2027-2032) Table 62. Global Ondansetron Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Ondansetron Sales Value Market Share by Country (2021-2026) Table 64. Global Ondansetron Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Ondansetron Sales Value Market Share by Country (2027-2032) Table 66. Sun Pharmaceuticals Company Information Table 67. Sun Pharmaceuticals Business Overview Table 68. Sun Pharmaceuticals Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 69. Sun Pharmaceuticals Ondansetron Product Portfolio Table 70. Sun Pharmaceuticals Recent Development Table 71. Sandoz Company Information Table 72. Sandoz Business Overview Table 73. Sandoz Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 74. Sandoz Ondansetron Product Portfolio Table 75. Sandoz Recent Development Table 76. Qilu Pharmaceutical Company Information Table 77. Qilu Pharmaceutical Business Overview Table 78. Qilu Pharmaceutical Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 79. Qilu Pharmaceutical Ondansetron Product Portfolio Table 80. Qilu Pharmaceutical Recent Development Table 81. Fuan Pharmaceutical Company Information Table 82. Fuan Pharmaceutical Business Overview Table 83. Fuan Pharmaceutical Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 84. Fuan Pharmaceutical Ondansetron Product Portfolio Table 85. Fuan Pharmaceutical Recent Development Table 86. PKU HealthCare Company Information Table 87. PKU HealthCare Business Overview Table 88. PKU HealthCare Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 89. PKU HealthCare Ondansetron Product Portfolio Table 90. PKU HealthCare Recent Development Table 91. Wockhardt Company Information Table 92. Wockhardt Business Overview Table 93. Wockhardt Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 94. Wockhardt Ondansetron Product Portfolio Table 95. Wockhardt Recent Development Table 96. Aelida Healthcare Company Information Table 97. Aelida Healthcare Business Overview Table 98. Aelida Healthcare Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 99. Aelida Healthcare Ondansetron Product Portfolio Table 100. Aelida Healthcare Recent Development Table 101. Beijing Sciecure Pharmaceutical Company Information Table 102. Beijing Sciecure Pharmaceutical Business Overview Table 103. Beijing Sciecure Pharmaceutical Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 104. Beijing Sciecure Pharmaceutical Ondansetron Product Portfolio Table 105. Beijing Sciecure Pharmaceutical Recent Development Table 106. Jiangsu Hengrui Pharmaceuticals Company Information Table 107. Jiangsu Hengrui Pharmaceuticals Business Overview Table 108. Jiangsu Hengrui Pharmaceuticals Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 109. Jiangsu Hengrui Pharmaceuticals Ondansetron Product Portfolio Table 110. Jiangsu Hengrui Pharmaceuticals Recent Development Table 111. Fosun Pharma Company Information Table 112. Fosun Pharma Business Overview Table 113. Fosun Pharma Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 114. Fosun Pharma Ondansetron Product Portfolio Table 115. Fosun Pharma Recent Development Table 116. Harbin Medisan Company Information Table 117. Harbin Medisan Business Overview Table 118. Harbin Medisan Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 119. Harbin Medisan Ondansetron Product Portfolio Table 120. Harbin Medisan Recent Development Table 121. CTX Lifesciences Company Information Table 122. CTX Lifesciences Business Overview Table 123. CTX Lifesciences Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 124. CTX Lifesciences Ondansetron Product Portfolio Table 125. CTX Lifesciences Recent Development Table 126. Pfizer Company Information Table 127. Pfizer Business Overview Table 128. Pfizer Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 129. Pfizer Ondansetron Product Portfolio Table 130. Pfizer Recent Development Table 131. Viatris Company Information Table 132. Viatris Business Overview Table 133. Viatris Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 134. Viatris Ondansetron Product Portfolio Table 135. Viatris Recent Development Table 136. Dr. Reddy's Laboratories Company Information Table 137. Dr. Reddy's Laboratories Business Overview Table 138. Dr. Reddy's Laboratories Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 139. Dr. Reddy's Laboratories Ondansetron Product Portfolio Table 140. Dr. Reddy's Laboratories Recent Development Table 141. Aurobindo Pharma Company Information Table 142. Aurobindo Pharma Business Overview Table 143. Aurobindo Pharma Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 144. Aurobindo Pharma Ondansetron Product Portfolio Table 145. Aurobindo Pharma Recent Development Table 146. Zydus Lifesciences Company Information Table 147. Zydus Lifesciences Business Overview Table 148. Zydus Lifesciences Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 149. Zydus Lifesciences Ondansetron Product Portfolio Table 150. Zydus Lifesciences Recent Development Table 151. Lupin Company Information Table 152. Lupin Business Overview Table 153. Lupin Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 154. Lupin Ondansetron Product Portfolio Table 155. Lupin Recent Development Table 156. Hikma Pharmaceuticals Company Information Table 157. Hikma Pharmaceuticals Business Overview Table 158. Hikma Pharmaceuticals Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 159. Hikma Pharmaceuticals Ondansetron Product Portfolio Table 160. Hikma Pharmaceuticals Recent Development Table 161. Fresenius Kabi Company Information Table 162. Fresenius Kabi Business Overview Table 163. Fresenius Kabi Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 164. Fresenius Kabi Ondansetron Product Portfolio Table 165. Fresenius Kabi Recent Development Table 166. Baxter Pharmaceuticals Company Information Table 167. Baxter Pharmaceuticals Business Overview Table 168. Baxter Pharmaceuticals Ondansetron Sales (kg), Value (US$ Million), Price (USD/g) and Gross Margin (2021-2026) Table 169. Baxter Pharmaceuticals Ondansetron Product Portfolio Table 170. Baxter Pharmaceuticals Recent Development Table 171. Key Raw Materials Table 172. Raw Materials Key Suppliers Table 173. Ondansetron Distributors List Table 174. Ondansetron Customers List Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. Ondansetron Product Image Figure 2. Global Ondansetron Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ondansetron Sales Value (2021-2032) & (US$ Million) Figure 4. Global Ondansetron Sales (2021-2032) & (kg) Figure 5. Global Ondansetron Sales Average Price (USD/g) & (2021-2032) Figure 6. Global Ondansetron Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Tablets (including ODT) Image Figure 10. Injection Image Figure 11. ODF/OSF Image Figure 12. Other Image Figure 13. Global Ondansetron Sales Volume by Type (2021 VS 2025 VS 2032) & (kg) Figure 14. Global Ondansetron Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Ondansetron Sales Volume Share by Type (2021-2032) Figure 16. Global Ondansetron Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Ondansetron Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Ondansetron Sales Value Share by Type (2021-2032) Figure 19. Hospital pharmacies Image Figure 20. Retail pharmacies Image Figure 21. Online pharmacies Image Figure 22. Global Ondansetron Sales Volume by Application (2021 VS 2025 VS 2032) & (kg) Figure 23. Global Ondansetron Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Ondansetron Sales Volume Share by Application (2021-2032) Figure 25. Global Ondansetron Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Ondansetron Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Ondansetron Sales Value Share by Application (2021-2032) Figure 28. Global Ondansetron Sales by Region: 2021 VS 2025 VS 2032 (kg) Figure 29. Global Ondansetron Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Ondansetron Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Ondansetron Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Ondansetron Sales Value (2021-2032) & (US$ Million) Figure 33. North America Ondansetron Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Ondansetron Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Ondansetron Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Ondansetron Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Ondansetron Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Ondansetron Sales Value (2021-2032) & (US$ Million) Figure 39. South America Ondansetron Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Ondansetron Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Ondansetron Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Ondansetron Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Ondansetron Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Ondansetron Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Ondansetron Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Ondansetron Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets (including ODT)
  • Injection
  • ODF/OSF
  • Other
Applications
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
Companies covered
  • Sun Pharmaceuticals
  • Sandoz
  • Qilu Pharmaceutical
  • Fuan Pharmaceutical
  • PKU HealthCare
  • Wockhardt
  • Aelida Healthcare
  • Beijing Sciecure Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Fosun Pharma
  • Harbin Medisan
  • CTX Lifesciences
  • Pfizer
  • Viatris
  • Dr. Reddy's Laboratories
  • Aurobindo Pharma
  • Zydus Lifesciences
  • Lupin
  • Hikma Pharmaceuticals
  • Fresenius Kabi
  • Baxter Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Ondansetron Sales Value (2021-2032)
  4. 1.2.2 Global Ondansetron Sales Volume (2021-2032)
  5. 1.2.3 Global Ondansetron Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Ondansetron Market Dynamics
  1. 2.1 Ondansetron Industry Trends
  2. 2.2 Ondansetron Industry Drivers
  3. 2.3 Ondansetron Industry Opportunities and Challenges
  4. 2.4 Ondansetron Industry Restraints
3 Ondansetron Market by Company
  1. 3.1 Global Ondansetron Company Revenue Ranking in 2025
  2. 3.2 Global Ondansetron Revenue by Company (2021-2026)
  3. 3.3 Global Ondansetron Sales Volume by Company (2021-2026)
  4. 3.4 Global Ondansetron Average Price by Company (2021-2026)
  5. 3.5 Global Ondansetron Company Ranking (2024-2026)
  6. 3.6 Global Ondansetron Company Manufacturing Base and Headquarters
  7. 3.7 Global Ondansetron Company Product Type and Application
  8. 3.8 Global Ondansetron Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Ondansetron Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Ondansetron Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Ondansetron Market by Type
  1. 4.1 Ondansetron Type Introduction
  2. 4.1.1 Tablets (including ODT)
  3. 4.1.2 Injection
  4. 4.1.3 ODF/OSF
  5. 4.1.4 Other
  6. 4.2 Global Ondansetron Sales Volume by Type
  7. 4.2.1 Global Ondansetron Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Ondansetron Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Ondansetron Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Ondansetron Sales Value by Type
  11. 4.3.1 Global Ondansetron Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Ondansetron Sales Value by Type (2021-2032)
  13. 4.3.3 Global Ondansetron Sales Value Share by Type (2021-2032)
5 Ondansetron Market by Application
  1. 5.1 Ondansetron Application Introduction
  2. 5.1.1 Hospital pharmacies
  3. 5.1.2 Retail pharmacies
  4. 5.1.3 Online pharmacies
  5. 5.2 Global Ondansetron Sales Volume by Application
  6. 5.2.1 Global Ondansetron Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Ondansetron Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Ondansetron Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Ondansetron Sales Value by Application
  10. 5.3.1 Global Ondansetron Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Ondansetron Sales Value by Application (2021-2032)
  12. 5.3.3 Global Ondansetron Sales Value Share by Application (2021-2032)
6 Ondansetron Regional Sales and Value Analysis
  1. 6.1 Global Ondansetron Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Ondansetron Sales by Region (2021-2032)
  3. 6.2.1 Global Ondansetron Sales by Region: 2021-2026
  4. 6.2.2 Global Ondansetron Sales by Region (2027-2032)
  5. 6.3 Global Ondansetron Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Ondansetron Sales Value by Region (2021-2032)
  7. 6.4.1 Global Ondansetron Sales Value by Region: 2021-2026
  8. 6.4.2 Global Ondansetron Sales Value by Region (2027-2032)
  9. 6.5 Global Ondansetron Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Ondansetron Sales Value (2021-2032)
  12. 6.6.2 North America Ondansetron Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Ondansetron Sales Value (2021-2032)
  15. 6.7.2 Europe Ondansetron Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Ondansetron Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Ondansetron Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Ondansetron Sales Value (2021-2032)
  21. 6.9.2 South America Ondansetron Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Ondansetron Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Ondansetron Sales Value Share by Country, 2025 VS 2032
7 Ondansetron Country-level Sales and Value Analysis
  1. 7.1 Global Ondansetron Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Ondansetron Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Ondansetron Sales by Country (2021-2032)
  4. 7.3.1 Global Ondansetron Sales by Country (2021-2026)
  5. 7.3.2 Global Ondansetron Sales by Country (2027-2032)
  6. 7.4 Global Ondansetron Sales Value by Country (2021-2032)
  7. 7.4.1 Global Ondansetron Sales Value by Country (2021-2026)
  8. 7.4.2 Global Ondansetron Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Ondansetron Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Ondansetron Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Ondansetron Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Ondansetron Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Ondansetron Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Ondansetron Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Ondansetron Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Ondansetron Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Ondansetron Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Ondansetron Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Ondansetron Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Ondansetron Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Ondansetron Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Ondansetron Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Ondansetron Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Ondansetron Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Ondansetron Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Ondansetron Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Ondansetron Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Ondansetron Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Ondansetron Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Ondansetron Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Ondansetron Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Ondansetron Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Ondansetron Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Ondansetron Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Ondansetron Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Ondansetron Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Ondansetron Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Ondansetron Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Ondansetron Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Ondansetron Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Ondansetron Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Ondansetron Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Ondansetron Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Ondansetron Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Ondansetron Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Ondansetron Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Ondansetron Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Ondansetron Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Ondansetron Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Ondansetron Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Ondansetron Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Ondansetron Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Ondansetron Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Ondansetron Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Ondansetron Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Ondansetron Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Ondansetron Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Ondansetron Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Ondansetron Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Ondansetron Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Ondansetron Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Ondansetron Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Ondansetron Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Ondansetron Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Ondansetron Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Ondansetron Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Ondansetron Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Ondansetron Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Ondansetron Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Ondansetron Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Ondansetron Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Ondansetron Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Ondansetron Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Ondansetron Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Ondansetron Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Ondansetron Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Ondansetron Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Ondansetron Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Ondansetron Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Ondansetron Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Ondansetron Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Ondansetron Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Ondansetron Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Ondansetron Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Ondansetron Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Ondansetron Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Ondansetron Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Ondansetron Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Ondansetron Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Ondansetron Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Ondansetron Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Ondansetron Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sun Pharmaceuticals
  2. 8.1.1 Sun Pharmaceuticals Company Information
  3. 8.1.2 Sun Pharmaceuticals Business Overview
  4. 8.1.3 Sun Pharmaceuticals Ondansetron Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sun Pharmaceuticals Ondansetron Product Portfolio
  6. 8.1.5 Sun Pharmaceuticals Recent Developments
  7. 8.2 Sandoz
  8. 8.2.1 Sandoz Company Information
  9. 8.2.2 Sandoz Business Overview
  10. 8.2.3 Sandoz Ondansetron Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sandoz Ondansetron Product Portfolio
  12. 8.2.5 Sandoz Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical Ondansetron Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical Ondansetron Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Fuan Pharmaceutical
  20. 8.4.1 Fuan Pharmaceutical Company Information
  21. 8.4.2 Fuan Pharmaceutical Business Overview
  22. 8.4.3 Fuan Pharmaceutical Ondansetron Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Fuan Pharmaceutical Ondansetron Product Portfolio
  24. 8.4.5 Fuan Pharmaceutical Recent Developments
  25. 8.5 PKU HealthCare
  26. 8.5.1 PKU HealthCare Company Information
  27. 8.5.2 PKU HealthCare Business Overview
  28. 8.5.3 PKU HealthCare Ondansetron Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 PKU HealthCare Ondansetron Product Portfolio
  30. 8.5.5 PKU HealthCare Recent Developments
  31. 8.6 Wockhardt
  32. 8.6.1 Wockhardt Company Information
  33. 8.6.2 Wockhardt Business Overview
  34. 8.6.3 Wockhardt Ondansetron Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Wockhardt Ondansetron Product Portfolio
  36. 8.6.5 Wockhardt Recent Developments
  37. 8.7 Aelida Healthcare
  38. 8.7.1 Aelida Healthcare Company Information
  39. 8.7.2 Aelida Healthcare Business Overview
  40. 8.7.3 Aelida Healthcare Ondansetron Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Aelida Healthcare Ondansetron Product Portfolio
  42. 8.7.5 Aelida Healthcare Recent Developments
  43. 8.8 Beijing Sciecure Pharmaceutical
  44. 8.8.1 Beijing Sciecure Pharmaceutical Company Information
  45. 8.8.2 Beijing Sciecure Pharmaceutical Business Overview
  46. 8.8.3 Beijing Sciecure Pharmaceutical Ondansetron Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Beijing Sciecure Pharmaceutical Ondansetron Product Portfolio
  48. 8.8.5 Beijing Sciecure Pharmaceutical Recent Developments
  49. 8.9 Jiangsu Hengrui Pharmaceuticals
  50. 8.9.1 Jiangsu Hengrui Pharmaceuticals Company Information
  51. 8.9.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  52. 8.9.3 Jiangsu Hengrui Pharmaceuticals Ondansetron Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Hengrui Pharmaceuticals Ondansetron Product Portfolio
  54. 8.9.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  55. 8.10 Fosun Pharma
  56. 8.10.1 Fosun Pharma Company Information
  57. 8.10.2 Fosun Pharma Business Overview
  58. 8.10.3 Fosun Pharma Ondansetron Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Fosun Pharma Ondansetron Product Portfolio
  60. 8.10.5 Fosun Pharma Recent Developments
  61. 8.11 Harbin Medisan
  62. 8.11.1 Harbin Medisan Company Information
  63. 8.11.2 Harbin Medisan Business Overview
  64. 8.11.3 Harbin Medisan Ondansetron Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Harbin Medisan Ondansetron Product Portfolio
  66. 8.11.5 Harbin Medisan Recent Developments
  67. 8.12 CTX Lifesciences
  68. 8.12.1 CTX Lifesciences Company Information
  69. 8.12.2 CTX Lifesciences Business Overview
  70. 8.12.3 CTX Lifesciences Ondansetron Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 CTX Lifesciences Ondansetron Product Portfolio
  72. 8.12.5 CTX Lifesciences Recent Developments
  73. 8.13 Pfizer
  74. 8.13.1 Pfizer Company Information
  75. 8.13.2 Pfizer Business Overview
  76. 8.13.3 Pfizer Ondansetron Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer Ondansetron Product Portfolio
  78. 8.13.5 Pfizer Recent Developments
  79. 8.14 Viatris
  80. 8.14.1 Viatris Company Information
  81. 8.14.2 Viatris Business Overview
  82. 8.14.3 Viatris Ondansetron Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Viatris Ondansetron Product Portfolio
  84. 8.14.5 Viatris Recent Developments
  85. 8.15 Dr. Reddy's Laboratories
  86. 8.15.1 Dr. Reddy's Laboratories Company Information
  87. 8.15.2 Dr. Reddy's Laboratories Business Overview
  88. 8.15.3 Dr. Reddy's Laboratories Ondansetron Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Dr. Reddy's Laboratories Ondansetron Product Portfolio
  90. 8.15.5 Dr. Reddy's Laboratories Recent Developments
  91. 8.16 Aurobindo Pharma
  92. 8.16.1 Aurobindo Pharma Company Information
  93. 8.16.2 Aurobindo Pharma Business Overview
  94. 8.16.3 Aurobindo Pharma Ondansetron Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Aurobindo Pharma Ondansetron Product Portfolio
  96. 8.16.5 Aurobindo Pharma Recent Developments
  97. 8.17 Zydus Lifesciences
  98. 8.17.1 Zydus Lifesciences Company Information
  99. 8.17.2 Zydus Lifesciences Business Overview
  100. 8.17.3 Zydus Lifesciences Ondansetron Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Zydus Lifesciences Ondansetron Product Portfolio
  102. 8.17.5 Zydus Lifesciences Recent Developments
  103. 8.18 Lupin
  104. 8.18.1 Lupin Company Information
  105. 8.18.2 Lupin Business Overview
  106. 8.18.3 Lupin Ondansetron Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Lupin Ondansetron Product Portfolio
  108. 8.18.5 Lupin Recent Developments
  109. 8.19 Hikma Pharmaceuticals
  110. 8.19.1 Hikma Pharmaceuticals Company Information
  111. 8.19.2 Hikma Pharmaceuticals Business Overview
  112. 8.19.3 Hikma Pharmaceuticals Ondansetron Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Hikma Pharmaceuticals Ondansetron Product Portfolio
  114. 8.19.5 Hikma Pharmaceuticals Recent Developments
  115. 8.20 Fresenius Kabi
  116. 8.20.1 Fresenius Kabi Company Information
  117. 8.20.2 Fresenius Kabi Business Overview
  118. 8.20.3 Fresenius Kabi Ondansetron Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Fresenius Kabi Ondansetron Product Portfolio
  120. 8.20.5 Fresenius Kabi Recent Developments
  121. 8.21 Baxter Pharmaceuticals
  122. 8.21.1 Baxter Pharmaceuticals Company Information
  123. 8.21.2 Baxter Pharmaceuticals Business Overview
  124. 8.21.3 Baxter Pharmaceuticals Ondansetron Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Baxter Pharmaceuticals Ondansetron Product Portfolio
  126. 8.21.5 Baxter Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Ondansetron Value Chain Analysis
  2. 9.1.1 Ondansetron Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Ondansetron Sales Mode & Process
  6. 9.2 Ondansetron Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Ondansetron Distributors
  9. 9.2.3 Ondansetron Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst